Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7762)
All Articles published online
|
Publishing Process of This Article
|
Jul 24, 2020 (publication date) through Nov 20, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Oncology
ISSN
2218-4333
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| de Salins V, Loganadane G, Joly C, Abulizi M, Nourieh M, Boussion H, Belkacemi Y, Tournigand C, Kempf E. Complete response in anaplastic lymphoma kinase–rearranged oncocytic thyroid cancer: A case report and review of literature. World J Clin Oncol 2020; 11(7): 495-503 [PMID: 32821654 DOI: 10.5306/wjco.v11.i7.495] |
|
|
|
| ©2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA | |
| For: | de Salins V, Loganadane G, Joly C, Abulizi M, Nourieh M, Boussion H, Belkacemi Y, Tournigand C, Kempf E. Complete response in anaplastic lymphoma kinase–rearranged oncocytic thyroid cancer: A case report and review of literature. World J Clin Oncol 2020; 11(7): 495-503 [PMID: 32821654 DOI: 10.5306/wjco.v11.i7.495] |
|---|---|
| URL: | https://www.wjgnet.com/2218-4333/full/v11/i7/495.htm |
| Number | Citing Articles |
| 1 |
Viktoria F. Koehler, C. Benedikt Westphalen, James Nagarajah, Mathias Zacherl, Christine Spitzweg. Molekular zielgerichtete Therapien beim radiojodrefraktären differenzierten Schilddrüsenkarzinom – Update 2022. Die Onkologie 2022; 28(8): 649 doi: 10.1007/s00761-022-01195-8
|
| 2 |
Ariadna Tibau, Thomas J Hwang, Jerry Avorn, Aaron S Kesselheim. Clinical value of guideline recommended molecular targets and genome targeted cancer therapies: cross sectional study. BMJ 2024; 386: e079126 doi: 10.1136/bmj-2023-079126
|
| 3 |
Matthew D. Ringel, Julie Ann Sosa, Zubair Baloch, Lindsay Bischoff, Gary Bloom, Gregory A. Brent, Pamela L. Brock, Roger Chou, Robert R. Flavell, Whitney Goldner, Elizabeth G. Grubbs, Megan Haymart, Steven M. Larson, Angela M. Leung, Joseph Osborne, John A. Ridge, Bruce Robinson, David L. Steward, Ralph P. Tufano, Lori J. Wirth. 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer. Thyroid® 2025; 35(8): 841 doi: 10.1177/10507256251363120
|
| 4 |
Carrie C. Lubitz, Peter M. Sadow, Gilbert H. Daniels, Lori J. Wirth. Progress in Treating Advanced Thyroid Cancers in the Era of Targeted Therapy. Thyroid 2021; doi: 10.1089/thy.2020.0962
|
| 5 |
Ying-Hsia Chu. This is Your Thyroid on Drugs. Surgical Pathology Clinics 2023; 16(1): 57 doi: 10.1016/j.path.2022.09.007
|
| 6 |
Ying-Hsia Chu, Peter M. Sadow. Kinase fusion-related thyroid carcinomas: distinct pathologic entities with evolving diagnostic implications. Diagnostic Histopathology 2021; 27(6): 252 doi: 10.1016/j.mpdhp.2021.03.003
|
| 7 |
Karen M. Yun, Ezra E.W. Cohen. An Era of Advances in Systemic Therapies for Advanced Thyroid Cancer. JCO Oncology Practice 2024; 20(7): 899 doi: 10.1200/OP.23.00747
|
| 8 |
Matti L. Gild, Martyn Bullock, Venessa Tsang, Roderick J. Clifton-Bligh, Bruce G. Robinson, Lori J. Wirth. Challenges and Strategies to Combat Resistance Mechanisms in Thyroid Cancer Therapeutics. Thyroid 2023; 33(6): 682 doi: 10.1089/thy.2022.0704
|
| 9 |
Simion Chiosea, Steven P Hodak, Linwah Yip, Devaprabu Abraham, Chelsey Baldwin, Zubair Baloch, Seza A Gulec, Zeina C Hannoush, Bryan R Haugen, Lija Joseph, Atil Y Kargi, Elham Khanafshar, Masha J Livhits, Bryan McIver, Kepal Patel, Snehal G Patel, Gregory W Randolph, Ashok R Shaha, Jyotirmay Sharma, Nikolaos Stathatos, Annemieke van Zante, Sally E Carty, Yuri E Nikiforov, Marina N Nikiforova. Molecular Profiling of 50 734 Bethesda III-VI Thyroid Nodules by ThyroSeq v3: Implications for Personalized Management. The Journal of Clinical Endocrinology & Metabolism 2023; 108(11): 2999 doi: 10.1210/clinem/dgad220
|
| 10 |
Young Kee Shong. Current Status and Future Perspective of the Treatment for Radioiodine Refractory Differentiated Thyroid Cancer. International Journal of Thyroidology 2021; 14(2): 98 doi: 10.11106/ijt.2021.14.2.98
|
| 11 |
Svetlana N. Aleksakhina, Evgeny N. Imyanitov. Cancer Therapy Guided by Mutation Tests: Current Status and Perspectives. International Journal of Molecular Sciences 2021; 22(20): 10931 doi: 10.3390/ijms222010931
|
| 12 |
Alyaksandr V. Nikitski, Vincenzo Condello, Saurabh S. Divakaran, Yuri E. Nikiforov. Inhibition of ALK-Signaling Overcomes STRN-ALK-Induced Downregulation of the Sodium Iodine Symporter and Restores Radioiodine Uptake in Thyroid Cells. Thyroid 2023; 33(4): 464 doi: 10.1089/thy.2022.0533
|
| 13 |
Kajetan Kiełbowski, Justyna Żychowska, Rafał Becht. Anaplastic lymphoma kinase inhibitors—a review of anticancer properties, clinical efficacy, and resistance mechanisms. Frontiers in Pharmacology 2023; 14 doi: 10.3389/fphar.2023.1285374
|
| 14 |
Hervé Bischoff, Antonin Fattori, Fabien Moinard-Butot, Olivier Schneegans, Pablo Diaz, Damien Reita, Valérie Rimelen, Anne-Claire Voegeli, Laura Bender. First Report of SPECC1L::ALK Fusion in Medullary Thyroid Carcinoma with Remarkable Response to Alectinib. Thyroid® 2025; doi: 10.1089/thy.2025.0017
|
| 15 |
Young Shin Song, Young Joo Park. Thyroid FNA Cytology. 2023; : 697 doi: 10.1007/978-981-99-6782-7_82
|
| 16 |
Geethu Babu, Rejnish Ravikumar, Malu Rafi, Lekha Madhavan Nair, Zuzaki Sharafuddin, John Mathew, Nijo Jose, Kainickal Cessal Thommachan. Thyroid Cancer - The Road From Genes to Successful Treatment. 2023; doi: 10.5772/intechopen.106462
|
| 17 |
Lucheng Zhu, Shenglin Ma, Bing Xia. Remarkable response to alectinib for metastatic papillary thyroid cancer with STRN-ALK fusion: A case report. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.1009076
|
| 18 |
Ying-Hsia Chu, Peter M. Sadow. Kinase Fusion–Related Thyroid Carcinomas: Towards Predictive Models for Advanced Actionable Diagnostics. Endocrine Pathology 2022; 33(4): 421 doi: 10.1007/s12022-022-09739-9
|
| 19 |
Sabrina K. Salgia, Ameish Govindarajan, Ravi Salgia, Sumanta K. Pal. ALK-Directed Therapy in Non-NSCLC Malignancies: Are We Ready?. JCO Precision Oncology 2021; (5): 767 doi: 10.1200/PO.21.00078
|
| 20 |
Elisabetta Macerola, Anello Marcello Poma, Paola Vignali, Agnese Proietti, Clara Ugolini, Liborio Torregrossa, Alessio Basolo, Rossella Elisei, Ferruccio Santini, Fulvio Basolo. Predictive Biomarkers in Thyroid Cancer. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.901004
|
| 21 |
Silvia Buriolla, Giulia Zapelloni, Claudia Cipri, Giacomo Pelizzari, Alessandro Follador, Francesco Cortiula. Alectinib for the treatment of papillary thyroid carcinoma harbouring STRN – ALK fusion. European Journal of Cancer 2025; 216: 115193 doi: 10.1016/j.ejca.2024.115193
|